Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Outline of Final Research Achievements |
Among the intractable neurodegenerative diseases, amyotrophic lateral sclerosis(ALS) and frontotemporal lobar degeneration(FTLD), the mutation of C9ORF72 gene is the most common mutation in ALS/FTLD(C9ALS/FTLD). The toxicity of proteins produced by repeat-associated non-ATG(RAN) translation is though to be associated with pathogenesis of C9ALS/FTLD. Decreasing this toxicity by regulating RAN translation leads to one of the novel therapy. We identified suppressive modifier(s) of RAN translation by genetic analysis using Drosophila model for ALS/FTLD related to mutation of C9ORF72 gene.
|